AMACR
- Known as:
- AMACR
- Catalog number:
- 001509A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- AMACR
Related genes to: AMACR
- Gene:
- AMACR NIH gene
- Name:
- alpha-methylacyl-CoA racemase
- Previous symbol:
- -
- Synonyms:
- RACE, P504S
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-19
- Date modifiied:
- 2016-12-13
Related products to: AMACR
Related articles to: AMACR
- Prostate cancer preferentially metastasizes to bone and lymph nodes. Testicular metastases are exceptionally rare and are typically observed in the setting of advanced polymetastatic disease. Their presentation as an isolated oligometastatic relapse remains highly unusual. We report the case of a 76-year-old patient followed since 2019 for de novo metastatic prostate adenocarcinoma, initially treated with androgen deprivation therapy (ADT) with a complete response, who presented in March 2026 with a left testicular mass. Germ cell tumor markers were negative, while prostate-specific antigen (PSA) was elevated at 30 ng/mL. Prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET-CT) demonstrated increased uptake involving both the testis and the peri-scrotal region. A radical inguinal orchiectomy was performed. Immunohistochemical analysis showed strong expression of prostein (P501S) and alpha-methylacyl-CoA racemase (AMACR), confirming the prostatic origin of the lesion. Postoperatively, systemic treatment was intensified using combined androgen deprivation therapy with abiraterone acetate, resulting in a marked decline in PSA levels. Testicular dissemination of prostate adenocarcinoma may occur through retrograde venous or lymphatic pathways. Diagnosis relies on advanced molecular imaging and immunohistochemistry, particularly in cases with reduced PSA expression. This case highlights the relevance of a multimodal strategy in oligometastatic disease, combining metastasis-directed surgery and intensified systemic therapy. - Source: PubMed
Publication date: 2026/08/26
Harchaoui Mohamed AmineMasaoudi BrahimAzzakhmam MustaphaAlami MohammedAmeur Ahmed - To explore the value and significance of tripleimmunohistochemical detection of alpha-methylacyl-CoAracemase (AMACR), p63 and Ki-67 in the pathologicaldiagnosis of prostate cancer. - Source: PubMed
Niu MingZhao DanboHe RuixueQin LingLi ZhikaiZhang SideChen Lijun - Prostate lesions constitute a major cause of morbidity and mortality in Nigerian adult males. Prostate cancer (Pca) is now being reported as the second most frequently diagnosed malignancy in adult males. On some occasions, histopathological results may be inconclusive with the tissue sample tagged 'suspicious' of prostate cancer. Immunohistochemistry using Alpha methyl acyl CoA racemase (AMACR) and High molecular weight cytokeratin (HMWCK) can be used to clarify such cases. The study aims to evaluate the role of immunohistochemistry in resolving diagnostic dilemmas following core needle prostate biopsy. - Source: PubMed
Publication date: 2026/08/07
Nnamani Christian SundayUzoigwe Chukwuma JosephAnyimba Solomon KenechukwuNzegwu Martin ArinzeOsuogu Edegbe Felix - Renal cell carcinoma (RCC) with fibromyomatous stroma (RCC-FMS) was classified as an "emerging/provisional" entity in the 2016 WHO classification of tumors, specifically categorized as RCC with (vascular) fibromyomatous stroma. However, it was not included in the 2022 WHO classification. Renal cell carcinoma with hemangioblastoma (RCC-HB)-like features has also been reported infrequently in recent years. RCC-HB-like features and fibromyomatous stroma is quite rare, with only two reports in the literature. This report describes a rare tumor of RCC-HB-like features and fibromyomatous stroma associated with TSC1 mutations. A female patient was incidentally discovered a right renal mass during a routine physical examination conducted 2 weeks prior. Histology revealed that the tumor consisted of three distinct components: clear cell papillary renal cell tumor (CCPRCT)-like areas, fibromyomatous stroma, and HB-like areas. Immunohistochemical staining showed that the CCPRCT-like components exhibited basolateral, cup-shaped CAIX staining and were diffusely positive for AE1/AE3, CK7, and PAX-8, partially positive for AMACR/P504S, and weakly positive for CD10. The fibromyomatous stroma was positive for H-caldesmon, desmin, and SMA. In the HB-like components, α-inhibin, ERG, CD34, CAIX, and vimentin were all diffusely positive, CD10 was partially positive, and PAX-8 showed scattered, weak positivity. Whether RCC-HB features and fibromyomatous stroma can be regarded as a distinct subtype of RCC remains to be discussed by accumulation of more cases. - Source: PubMed
Publication date: 2026/08/23
Yao ShiyunHuang JinghuiWang MingfaQuan Chunji - Metanephric adenoma (MA) is a rare benign renal neoplasm characterized by recurrent BRAF V600E mutations in ∼80% to 90% of cases. The molecular drivers in BRAF V600E‑negative MAs remain poorly understood, although rare kinase fusions have been reported. Here, we present a multi‑institutional series of 7 BRAF V600E‑negative MAs with confirmed kinase fusions. The patients included 5 women and 2 men, with a median age of 43 years (range: 24 to 62 y). All tumors were uncapsulated and exhibited typical MA histology. Notably, leaf‑like structures formed by branching dilated tubules surrounding dense small acini were observed in 4 of 7 cases, and thyroid follicle‑like structures and/or microcystic/reticular patterns were observed in 3 of 7 cases. The majority of cases showed marked paucity of edematous or fibrous stroma. By immunohistochemistry, all cases were diffusely positive for WT1 and CD57, negative for BRAF V600E (clone VE1), and largely negative for CK7 and AMACR. Targeted RNA sequencing identified fusions involving RET (CCDC6::RET in 2 cases, ANKRD26::RET in 1), ALK (STRN::ALK in 2), ROS1 (RDX::ROS1 in 1), and BRAF (CUX1::BRAF in 1). All fusions preserved the kinase domain of the respective genes. Fluorescence in situ hybridization or reverse‑transcriptase PCR confirmed the rearrangements in available cases. In contrast, targeted RNA sequencing of 7 BRAF V600E‑mutant MAs revealed no kinase fusions. All patients underwent partial nephrectomy and remained disease‑free during follow‑up (median: 18 mo, range: 14 to 115 mo). Our findings demonstrate that kinase fusions, including RET, ALK, ROS1, and BRAF, represent alternative drivers in BRAF V600E‑negative MAs, expanding the molecular spectrum of MA. In VE1-negative cases with classic MA histology, targeted RNA sequencing for these fusions may serve as a useful diagnostic adjunct. - Source: PubMed
Publication date: 2026/08/25
Zhao MingYang XiaoqunWang QifengYu WenjuanFang RongXu JiayunQiu YimiaoZhang PingHe Huiying